白细胞介素-21及其受体在乳腺癌肿瘤引流淋巴结淋巴细胞中的表达

Breast disease Pub Date : 2022-01-01 DOI:10.3233/BD-220013

Sima Balouchi-Anaraki, Sara Mohammadsadeghi, Marzieh Norouzian, Reza Rasolmali, Abdol-Rasoul Talei, Fereshteh Mehdipour, Abbas Ghaderi

{"title":"白细胞介素-21及其受体在乳腺癌肿瘤引流淋巴结淋巴细胞中的表达","authors":"Sima Balouchi-Anaraki, Sara Mohammadsadeghi, Marzieh Norouzian, Reza Rasolmali, Abdol-Rasoul Talei, Fereshteh Mehdipour, Abbas Ghaderi","doi":"10.3233/BD-220013","DOIUrl":null,"url":null,"abstract":"Background: Interleukin-21 (IL-21) is produced by various cell types inducing positive and negative effects in immunity against tumors.Objective: To investigate the expression of IL-21 by CD4+T and IL-21 receptor (IL-21R) by B lymphocytes isolated from breast-tumor draining lymph nodes (TDLNs).Methods: Fresh lymph node samples were obtained from 45 patients with breast cancer. To assess IL-21 expression, mononuclear cells were briefly stimulated whereas IL-21R expression was assessed in unstimulated B cells. Cells were stained with antibodies for CD4, IL-21, CD19 and IL-21R and acquired by flow cytometry.Results: The frequency of IL-21+CD4+T cells did not show significant association with disease parameters. However, the geometric mean fluorescence intensity (gMFI) of IL-21 in CD4+T cells was significantly lower in patients with grade III tumor than grade I + II (P = 0.042). In non-involved LNs, the intensity of IL-21 was significantly higher in patients with stage II compared with stage III (P = 0.038) and correlated negatively with the number of involved LNs. The frequency of IL-21R+CD19+B cells was significantly higher in grade III than grade I + II (P = 0.037).Conclusion: The higher intensity of IL-21 in CD4+T cells showed association with good prognosticators in breast cancer and warrants further investigation of the role played by IL-21 in immunity against breast cancer.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Expression of Interleukin-21 and Interleukin-21 receptor in lymphocytes derived from tumor-draining lymph nodes of breast cancer.\",\"authors\":\"Sima Balouchi-Anaraki, Sara Mohammadsadeghi, Marzieh Norouzian, Reza Rasolmali, Abdol-Rasoul Talei, Fereshteh Mehdipour, Abbas Ghaderi\",\"doi\":\"10.3233/BD-220013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Interleukin-21 (IL-21) is produced by various cell types inducing positive and negative effects in immunity against tumors.Objective: To investigate the expression of IL-21 by CD4+T and IL-21 receptor (IL-21R) by B lymphocytes isolated from breast-tumor draining lymph nodes (TDLNs).Methods: Fresh lymph node samples were obtained from 45 patients with breast cancer. To assess IL-21 expression, mononuclear cells were briefly stimulated whereas IL-21R expression was assessed in unstimulated B cells. Cells were stained with antibodies for CD4, IL-21, CD19 and IL-21R and acquired by flow cytometry.Results: The frequency of IL-21+CD4+T cells did not show significant association with disease parameters. However, the geometric mean fluorescence intensity (gMFI) of IL-21 in CD4+T cells was significantly lower in patients with grade III tumor than grade I + II (P = 0.042). In non-involved LNs, the intensity of IL-21 was significantly higher in patients with stage II compared with stage III (P = 0.038) and correlated negatively with the number of involved LNs. The frequency of IL-21R+CD19+B cells was significantly higher in grade III than grade I + II (P = 0.037).Conclusion: The higher intensity of IL-21 in CD4+T cells showed association with good prognosticators in breast cancer and warrants further investigation of the role played by IL-21 in immunity against breast cancer.\",\"PeriodicalId\":9224,\"journal\":{\"name\":\"Breast disease\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3233/BD-220013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/BD-220013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

摘要

背景:白细胞介素-21 (IL-21)由多种细胞类型产生，在肿瘤免疫中诱导正、负作用。目的:探讨乳腺肿瘤引流淋巴结(tdln) B淋巴细胞CD4+T表达IL-21及IL-21受体(IL-21R)的变化。方法:选取45例乳腺癌患者的新鲜淋巴结标本。为了评估IL-21的表达，我们短暂刺激单个核细胞，而在未刺激的B细胞中评估IL-21R的表达。细胞用CD4、IL-21、CD19和IL-21R抗体染色，并通过流式细胞术获得。结果:IL-21+CD4+T细胞频率与疾病参数无显著相关性。而III级肿瘤患者CD4+T细胞中IL-21的几何平均荧光强度(gMFI)明显低于I + II级肿瘤患者(P = 0.042)。在未受累的LNs中，II期患者IL-21的强度明显高于III期(P = 0.038)，且与受累LNs的数量呈负相关。III级患者IL-21R+CD19+B细胞频率明显高于I + II级患者(P = 0.037)。结论:CD4+T细胞中IL-21水平升高与乳腺癌预后良好相关，值得进一步研究IL-21在乳腺癌免疫中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Expression of Interleukin-21 and Interleukin-21 receptor in lymphocytes derived from tumor-draining lymph nodes of breast cancer.

Background: Interleukin-21 (IL-21) is produced by various cell types inducing positive and negative effects in immunity against tumors.

Objective: To investigate the expression of IL-21 by CD4+T and IL-21 receptor (IL-21R) by B lymphocytes isolated from breast-tumor draining lymph nodes (TDLNs).

Methods: Fresh lymph node samples were obtained from 45 patients with breast cancer. To assess IL-21 expression, mononuclear cells were briefly stimulated whereas IL-21R expression was assessed in unstimulated B cells. Cells were stained with antibodies for CD4, IL-21, CD19 and IL-21R and acquired by flow cytometry.

Results: The frequency of IL-21+CD4+T cells did not show significant association with disease parameters. However, the geometric mean fluorescence intensity (gMFI) of IL-21 in CD4+T cells was significantly lower in patients with grade III tumor than grade I + II (P = 0.042). In non-involved LNs, the intensity of IL-21 was significantly higher in patients with stage II compared with stage III (P = 0.038) and correlated negatively with the number of involved LNs. The frequency of IL-21R+CD19+B cells was significantly higher in grade III than grade I + II (P = 0.037).

Conclusion: The higher intensity of IL-21 in CD4+T cells showed association with good prognosticators in breast cancer and warrants further investigation of the role played by IL-21 in immunity against breast cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Breast disease Medicine-Oncology

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.